NYSE:JNJ
Johnson & Johnson (JNJ)
Financials 
Technical Analysis 
Jun 8, 2026, 12:00 amThis summary was created by AI, based on 12 opinions in the last 12 months.
Johnson & Johnson (JNJ) has undergone significant changes, notably spinning off its orthopedics division to focus more on pharmaceuticals and medical devices, which are expected to drive higher growth and margins. Despite facing challenges such as ongoing talcum powder lawsuits and a history of stock price volatility post-earnings announcements, analysts highlight the strength of JNJ's drug pipeline and its solid performance in the pharmaceutical sector. Year-to-date, the company has seen considerable stock appreciation, driven by its robust research capabilities and a favorable drug pipeline. While some experts express caution regarding valuation and broader healthcare market pressures, there is a consensus on the potential for continued dividend growth and upside for long-term investors, especially when purchasing during market dips.
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
